Reportable Segment — Cost of Sales
Eli Lilly Reportable Segment — Cost of Sales increased by 6.1% to $3.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 60.8%, from $2.23B to $3.58B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Cost of Sales shows an upward trend with a 18.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A lower ratio relative to revenue suggests improved manufacturing efficiency or favorable product mix, while an increase may signal rising input costs or production inefficiencies.
Detailed definition
Includes the direct costs attributable to the production and distribution of the pharmaceutical products sold by the seg...
Peer comparison
Comparable to cost of goods sold (COGS) in segment reporting for global life sciences firms.
lly_segment_reportable_segment_cost_of_salesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.66B | $1.66B | $1.66B | $1.66B | $1.77B | $1.77B | $1.77B | $1.77B | $1.67B | $2.17B | $2.17B | $2.40B | $2.23B | $2.45B | $3.01B | $3.37B | $3.58B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +6.8% | +0.0% | +0.0% | +0.0% | -5.5% | +29.7% | +0.0% | +10.7% | -7.4% | +10.0% | +22.9% | +12.1% | +6.1% |
| YoY Change | — | — | — | — | +6.8% | +6.8% | +6.8% | +6.8% | -5.5% | +22.6% | +22.6% | +35.8% | +33.0% | +12.8% | +38.6% | +40.3% | +60.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — cost of sales?
- Eli Lilly (LLY) reported reportable segment — cost of sales of $3.58B in Q1 2026.
- How has Eli Lilly's reportable segment — cost of sales changed year-over-year?
- Eli Lilly's reportable segment — cost of sales increased by 60.8% year-over-year, from $2.23B to $3.58B.
- What is the long-term trend for Eli Lilly's reportable segment — cost of sales?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — cost of sales has grown at a 18.6% compound annual growth rate (CAGR), from $6.63B to $11.05B.
- What does reportable segment — cost of sales mean?
- The direct costs incurred to produce and deliver the goods sold by this segment.